Review



mmp14 antibody  (ABclonal Biotechnology)


Bioz Verified Symbol ABclonal Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    ABclonal Biotechnology mmp14 antibody
    ACLY and ALDOA tyrosine phosphorylation critically contributes to the activation of c-Myc, Oct4, Sox2, and specific downstream molecules. a PCR was used to evaluate the expression of the AXL , GALK1 , SDC2 , ITGA5 , FGF2 , HIF1A , <t>MMP14</t> , TWIST1 , VEGFA , and VEGFC genes in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). b c-Myc, Oct4 and Sox2-bound promoter sequences of AXL , GALK1 , SDC2 , or ITGA5 from -85--42, -95--43, -81--31, and -156--110 are indicated. c ChIP was used to assess the ability of c-Myc, Oct4, and Sox2 to bind to the AXL , GALK1 , SDC2 , or ITGA5 promoter regions in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). The data are presented as the means ± SDs
    Mmp14 Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mmp14+a2549+antibody/MT1-MMP+Rabbit+pAb/pmc12399764-202-43-51
    Average 93 stars, based on 4 article reviews
    mmp14 antibody - by Bioz Stars, 2026-10
    93/100 stars

    Images

    1) Product Images from "Focal adhesion kinase/Src family kinase axis-mediated tyrosine phosphorylation of metabolic enzymes facilitates tumor metastasis"

    Article Title: Focal adhesion kinase/Src family kinase axis-mediated tyrosine phosphorylation of metabolic enzymes facilitates tumor metastasis

    Journal: Signal Transduction and Targeted Therapy

    doi: 10.1038/s41392-025-02395-5

    ACLY and ALDOA tyrosine phosphorylation critically contributes to the activation of c-Myc, Oct4, Sox2, and specific downstream molecules. a PCR was used to evaluate the expression of the AXL , GALK1 , SDC2 , ITGA5 , FGF2 , HIF1A , MMP14 , TWIST1 , VEGFA , and VEGFC genes in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). b c-Myc, Oct4 and Sox2-bound promoter sequences of AXL , GALK1 , SDC2 , or ITGA5 from -85--42, -95--43, -81--31, and -156--110 are indicated. c ChIP was used to assess the ability of c-Myc, Oct4, and Sox2 to bind to the AXL , GALK1 , SDC2 , or ITGA5 promoter regions in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). The data are presented as the means ± SDs
    Figure Legend Snippet: ACLY and ALDOA tyrosine phosphorylation critically contributes to the activation of c-Myc, Oct4, Sox2, and specific downstream molecules. a PCR was used to evaluate the expression of the AXL , GALK1 , SDC2 , ITGA5 , FGF2 , HIF1A , MMP14 , TWIST1 , VEGFA , and VEGFC genes in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). b c-Myc, Oct4 and Sox2-bound promoter sequences of AXL , GALK1 , SDC2 , or ITGA5 from -85--42, -95--43, -81--31, and -156--110 are indicated. c ChIP was used to assess the ability of c-Myc, Oct4, and Sox2 to bind to the AXL , GALK1 , SDC2 , or ITGA5 promoter regions in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). The data are presented as the means ± SDs

    Techniques Used: Phospho-proteomics, Activation Assay, Expressing

    Quercetagitrin inhibits the tyrosine phosphorylation of ALDOA to block ESCC malignancy. a Molecular docking between quercetagitrin and ALDOA. Quercetagitrin (0, 10, or 25 μM) dose-dependently inhibited the phosphorylation of ALDOA Tyr174, Tyr302, or Tyr328 b and ALDOA activity and G3P production c in primary and metastatic KYSE410 and KYSE510 cells ( n = 3). d CETSA assay showing the interaction status between quercetagitrin (50 μM) and ALDOA in KYSE410 cells harboring vector (left of the upper panel in d ), ALDOA Y174A (right of the upper panel in d ), Y302A (left of the lower panel in d ), or Y328A (right of the lower panel in d ) mutants ( n = 5). The growth and invasion of ESCC cells incubated with quercetagitrin (25 μM) were assessed via MTS e and Matrigel-based transwell invasion assays ( n = 3) ( f ). g PCR assay showing that quercetagitrin (25 μM) inhibited the mRNA expression of MCM3 , MCM4 , MCM5 , MCM6 , MCM7 , CDC45 , CCND1 , CCNE1 , CDK2 , CDK6 , IL6 , and IL11 in primary KYSE410 cells ( n = 3). h PCR assay showing that quercetagitrin (25 μM) inhibited the mRNA expression of AXL , FGF2 , GALK1 , HIF1A , ITGA5 , MMP14 , SDC2 , TWIST1 , VEGFA , and VEGFC in metastatic KYSE410 cells ( n = 3). The data are presented as the means ± SDs. n.s., not significantly different; ** P < 0.01; *** P < 0.001
    Figure Legend Snippet: Quercetagitrin inhibits the tyrosine phosphorylation of ALDOA to block ESCC malignancy. a Molecular docking between quercetagitrin and ALDOA. Quercetagitrin (0, 10, or 25 μM) dose-dependently inhibited the phosphorylation of ALDOA Tyr174, Tyr302, or Tyr328 b and ALDOA activity and G3P production c in primary and metastatic KYSE410 and KYSE510 cells ( n = 3). d CETSA assay showing the interaction status between quercetagitrin (50 μM) and ALDOA in KYSE410 cells harboring vector (left of the upper panel in d ), ALDOA Y174A (right of the upper panel in d ), Y302A (left of the lower panel in d ), or Y328A (right of the lower panel in d ) mutants ( n = 5). The growth and invasion of ESCC cells incubated with quercetagitrin (25 μM) were assessed via MTS e and Matrigel-based transwell invasion assays ( n = 3) ( f ). g PCR assay showing that quercetagitrin (25 μM) inhibited the mRNA expression of MCM3 , MCM4 , MCM5 , MCM6 , MCM7 , CDC45 , CCND1 , CCNE1 , CDK2 , CDK6 , IL6 , and IL11 in primary KYSE410 cells ( n = 3). h PCR assay showing that quercetagitrin (25 μM) inhibited the mRNA expression of AXL , FGF2 , GALK1 , HIF1A , ITGA5 , MMP14 , SDC2 , TWIST1 , VEGFA , and VEGFC in metastatic KYSE410 cells ( n = 3). The data are presented as the means ± SDs. n.s., not significantly different; ** P < 0.01; *** P < 0.001

    Techniques Used: Phospho-proteomics, Blocking Assay, Activity Assay, Plasmid Preparation, Incubation, Expressing

    Related Articles

    other:

    Article Title: Nordihydroguaiaretic acid inhibits bladder cancer metastasis through suppression of α1,3-mannosyltransferase expression and LRFN4 N-glycosylation.
    Article Snippet: Endogenous peroxidase was blocked with 3% hydrogen peroxide for 10 min at room temperature, and non-specific binding was blocked using 10% normal goat serum (ZSGB-BIO, Beijing, China).



    Similar Products

    mmp14 antibody  (ABclonal Biotechnology)
    93
    ABclonal Biotechnology mmp14 antibody
    ACLY and ALDOA tyrosine phosphorylation critically contributes to the activation of c-Myc, Oct4, Sox2, and specific downstream molecules. a PCR was used to evaluate the expression of the AXL , GALK1 , SDC2 , ITGA5 , FGF2 , HIF1A , <t>MMP14</t> , TWIST1 , VEGFA , and VEGFC genes in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). b c-Myc, Oct4 and Sox2-bound promoter sequences of AXL , GALK1 , SDC2 , or ITGA5 from -85--42, -95--43, -81--31, and -156--110 are indicated. c ChIP was used to assess the ability of c-Myc, Oct4, and Sox2 to bind to the AXL , GALK1 , SDC2 , or ITGA5 promoter regions in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). The data are presented as the means ± SDs
    Mmp14 Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mmp14+a2549+antibody/MT1-MMP+Rabbit+pAb/pmc12399764-202-43-51
    Average 93 stars, based on 1 article reviews
    mmp14 antibody - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    mmp14 a2549 antibody  (ABclonal Biotechnology)
    90
    ABclonal Biotechnology mmp14 a2549 antibody
    ACLY and ALDOA tyrosine phosphorylation critically contributes to the activation of c-Myc, Oct4, Sox2, and specific downstream molecules. a PCR was used to evaluate the expression of the AXL , GALK1 , SDC2 , ITGA5 , FGF2 , HIF1A , <t>MMP14</t> , TWIST1 , VEGFA , and VEGFC genes in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). b c-Myc, Oct4 and Sox2-bound promoter sequences of AXL , GALK1 , SDC2 , or ITGA5 from -85--42, -95--43, -81--31, and -156--110 are indicated. c ChIP was used to assess the ability of c-Myc, Oct4, and Sox2 to bind to the AXL , GALK1 , SDC2 , or ITGA5 promoter regions in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). The data are presented as the means ± SDs
    Mmp14 A2549 Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mmp14+a2549+antibody/mmp14+antibody/pm40605099-83-45-48
    Average 90 stars, based on 1 article reviews
    mmp14 a2549 antibody - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ACLY and ALDOA tyrosine phosphorylation critically contributes to the activation of c-Myc, Oct4, Sox2, and specific downstream molecules. a PCR was used to evaluate the expression of the AXL , GALK1 , SDC2 , ITGA5 , FGF2 , HIF1A , MMP14 , TWIST1 , VEGFA , and VEGFC genes in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). b c-Myc, Oct4 and Sox2-bound promoter sequences of AXL , GALK1 , SDC2 , or ITGA5 from -85--42, -95--43, -81--31, and -156--110 are indicated. c ChIP was used to assess the ability of c-Myc, Oct4, and Sox2 to bind to the AXL , GALK1 , SDC2 , or ITGA5 promoter regions in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). The data are presented as the means ± SDs

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Focal adhesion kinase/Src family kinase axis-mediated tyrosine phosphorylation of metabolic enzymes facilitates tumor metastasis

    doi: 10.1038/s41392-025-02395-5

    Figure Lengend Snippet: ACLY and ALDOA tyrosine phosphorylation critically contributes to the activation of c-Myc, Oct4, Sox2, and specific downstream molecules. a PCR was used to evaluate the expression of the AXL , GALK1 , SDC2 , ITGA5 , FGF2 , HIF1A , MMP14 , TWIST1 , VEGFA , and VEGFC genes in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). b c-Myc, Oct4 and Sox2-bound promoter sequences of AXL , GALK1 , SDC2 , or ITGA5 from -85--42, -95--43, -81--31, and -156--110 are indicated. c ChIP was used to assess the ability of c-Myc, Oct4, and Sox2 to bind to the AXL , GALK1 , SDC2 , or ITGA5 promoter regions in metastatic KYSE410 cells harboring ACLY Y542A with or without OAA (1 μM), ALDOA Y174A, Y302A, or Y328A with or without G3P (1 μM) ( n = 3). The data are presented as the means ± SDs

    Article Snippet: The MCM3 antibody (Cat # A11475), MCM4 antibody (Cat # A9251), MCM5 antibody (Cat # A5008), MCM6 antibody (Cat # A1955), MCM7 antibody (Cat # A11325), CDC45 antibody (Cat # A16032), CCND1 antibody (Cat # A11022), CCNE1 antibody (Cat # A22360 ), and MMP14 antibody (Cat # A15691) were obtained from ABclonal.

    Techniques: Phospho-proteomics, Activation Assay, Expressing

    Quercetagitrin inhibits the tyrosine phosphorylation of ALDOA to block ESCC malignancy. a Molecular docking between quercetagitrin and ALDOA. Quercetagitrin (0, 10, or 25 μM) dose-dependently inhibited the phosphorylation of ALDOA Tyr174, Tyr302, or Tyr328 b and ALDOA activity and G3P production c in primary and metastatic KYSE410 and KYSE510 cells ( n = 3). d CETSA assay showing the interaction status between quercetagitrin (50 μM) and ALDOA in KYSE410 cells harboring vector (left of the upper panel in d ), ALDOA Y174A (right of the upper panel in d ), Y302A (left of the lower panel in d ), or Y328A (right of the lower panel in d ) mutants ( n = 5). The growth and invasion of ESCC cells incubated with quercetagitrin (25 μM) were assessed via MTS e and Matrigel-based transwell invasion assays ( n = 3) ( f ). g PCR assay showing that quercetagitrin (25 μM) inhibited the mRNA expression of MCM3 , MCM4 , MCM5 , MCM6 , MCM7 , CDC45 , CCND1 , CCNE1 , CDK2 , CDK6 , IL6 , and IL11 in primary KYSE410 cells ( n = 3). h PCR assay showing that quercetagitrin (25 μM) inhibited the mRNA expression of AXL , FGF2 , GALK1 , HIF1A , ITGA5 , MMP14 , SDC2 , TWIST1 , VEGFA , and VEGFC in metastatic KYSE410 cells ( n = 3). The data are presented as the means ± SDs. n.s., not significantly different; ** P < 0.01; *** P < 0.001

    Journal: Signal Transduction and Targeted Therapy

    Article Title: Focal adhesion kinase/Src family kinase axis-mediated tyrosine phosphorylation of metabolic enzymes facilitates tumor metastasis

    doi: 10.1038/s41392-025-02395-5

    Figure Lengend Snippet: Quercetagitrin inhibits the tyrosine phosphorylation of ALDOA to block ESCC malignancy. a Molecular docking between quercetagitrin and ALDOA. Quercetagitrin (0, 10, or 25 μM) dose-dependently inhibited the phosphorylation of ALDOA Tyr174, Tyr302, or Tyr328 b and ALDOA activity and G3P production c in primary and metastatic KYSE410 and KYSE510 cells ( n = 3). d CETSA assay showing the interaction status between quercetagitrin (50 μM) and ALDOA in KYSE410 cells harboring vector (left of the upper panel in d ), ALDOA Y174A (right of the upper panel in d ), Y302A (left of the lower panel in d ), or Y328A (right of the lower panel in d ) mutants ( n = 5). The growth and invasion of ESCC cells incubated with quercetagitrin (25 μM) were assessed via MTS e and Matrigel-based transwell invasion assays ( n = 3) ( f ). g PCR assay showing that quercetagitrin (25 μM) inhibited the mRNA expression of MCM3 , MCM4 , MCM5 , MCM6 , MCM7 , CDC45 , CCND1 , CCNE1 , CDK2 , CDK6 , IL6 , and IL11 in primary KYSE410 cells ( n = 3). h PCR assay showing that quercetagitrin (25 μM) inhibited the mRNA expression of AXL , FGF2 , GALK1 , HIF1A , ITGA5 , MMP14 , SDC2 , TWIST1 , VEGFA , and VEGFC in metastatic KYSE410 cells ( n = 3). The data are presented as the means ± SDs. n.s., not significantly different; ** P < 0.01; *** P < 0.001

    Article Snippet: The MCM3 antibody (Cat # A11475), MCM4 antibody (Cat # A9251), MCM5 antibody (Cat # A5008), MCM6 antibody (Cat # A1955), MCM7 antibody (Cat # A11325), CDC45 antibody (Cat # A16032), CCND1 antibody (Cat # A11022), CCNE1 antibody (Cat # A22360 ), and MMP14 antibody (Cat # A15691) were obtained from ABclonal.

    Techniques: Phospho-proteomics, Blocking Assay, Activity Assay, Plasmid Preparation, Incubation, Expressing